Immunotherapy with anti-CD20 compounds

This publication has 139 references indexed in Scilit:

• Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL
  Bone Marrow Transplantation, 2002
• Phosphoprotein Associated with Glycosphingolipid-Enriched Microdomains (Pag), a Novel Ubiquitously Expressed Transmembrane Adaptor Protein, Binds the Protein Tyrosine Kinase Csk and Is Involved in Regulation of T Cell Activation
  The Journal of Experimental Medicine, 2000
• CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB
  British Journal of Haematology, 1999
• Activation of the Calcium-permeable Cation Channel CD20 by α Subunits of the Gi Protein
  Journal of Biological Chemistry, 1997
• Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20
  Journal of Biological Chemistry, 1995
• Molecular mechanisms regulating CD19, CD20 and CD22 gene expression
  Immunology Today, 1994
• CD20: a regulator of cell-cycle progression of B lymphocytes
  Immunology Today, 1994
• Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.
  The Journal of cell biology, 1993
• CD20 monoclonal antibodies down‐regulate IgM at the surface of B cells
  European Journal of Immunology, 1993
• Cd20 (pan‐B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes
  Cytometry, 1993